Please login to the form below
kidney disease
This page shows the latest kidney disease news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca’s heart failure treatment recommended by NICE for expanded use
The recommendation from NICE now means that patients with HFmrEF or HFpEF have access to a disease-modifying therapy for the first time. ... Forxiga is already approved to treat patients with type 2 diabetes, HFrEF and chronic kidney disease in over 100
Latest news
-
AstraZeneca’s heart failure treatment approved for expanded use in US
Farxiga is already approved to treat patients with type 2 diabetes, HFrEF and chronic kidney disease in over 100 countries, including the US, EU, China and Japan.
-
AstraZeneca’s heart failure treatment approved for expanded use in EU
Forxiga, marketed as Farxiga in the US, is already approved to treat patients with type 2 diabetes, reduced ejection fraction and chronic kidney disease in over 100 countries, including the US,
-
Roche reports positive results for crovalimab as rare blood disease treatment
PNH causes a patient’s red blood cells to break apart, resulting in a range of debilitating symptoms such as anaemia, fatigue, blood clots and kidney disease. ... People with PNH may benefit from more options to achieve robust disease control with less
-
AstraZeneca to acquire CinCor Pharma in deal worth up to $1.8bn
Through the acquisition, AZ will gain access to baxdrostat (CIN-107), CinCor’s experimental aldosterone synthase inhibitor currently in development to treat conditions such as chronic kidney disease (CKD) and ... The deal also offers AZ the potential
-
New research shows potential to treat kidney disease with common medicines
Acute kidney injuries cause around 20% of all emergency hospital admissions in the UK. ... left with chronic kidney disease (CKD) and the remaining 70% at an almost 30-fold increased risk of developing CKD.
More from news
Approximately 29 fully matching, plus 159 partially matching documents found.
Latest Intelligence
-
Focusing on ‘treating the patient, not the disease’ can transform the outlook for cardiovascular disease
Treatment for patients with CVDs such as heart failure or chronic kidney disease often means needing to consult cardiologists and nephrologists separately, specialists who operate in silos. ... centre of that is recognition that CVDs like stroke, heart
-
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care. ... AstraZeneca's R&D centre in Cambridge, UK. Moderate to severe chronic kidney disease (CKD) is an under-recognised public health
-
Cortellis Drugs to Watch in 2020 report
4. Vadadustat is an inhibitor of hypoxiainducible factor (HIF)-prolyl hydroxylase (HIF-PH) from Akebia Therapeutics/ Mitsubishi Tanabe Pharma/Otsuka that targets anaemia in chronic kidney disease (CKD). ... Hypercholesterolemia is a major risk of
-
Case study: What we're made of
If we don’t drink enough water, it can lead to headaches, constipation, tiredness and more serious problems, such as urinary infections and kidney disease. ... This could be a side effect of a condition such as stroke, motor neurone disease, multiple
-
25 Women Leaders in UK Healthcare
The firm has just signed a long-term collaboration with AZ for the discovery of new drugs for chronic kidney disease and idiopathic pulmonary fibrosis (IPF). ... disease and applying machine learning, artificial intelligence and collapsing analysis to
More from intelligence
Approximately 1 fully matching, plus 21 partially matching documents found.
Latest appointments
-
Sanifit appoints Alexander Gold chief medical officer
Alex arrives here with first class operational and clinical development expertise in novel drug therapies, targeting cardiovascular and metabolic disease and kidney disease amongst others.
-
Spectrum appoints chief medical officer
of iron deficiency anaemia in adult patients with chronic kidney disease.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Putting prevention at the heart of the future of the NHS
Prioritising the prevention of cardiovascular disease (CVD) should be at the heart of plans to safeguard the long-term sustainability of the NHS. ... No disease area epitomises this reality better than CVD. Poor heart health leads to heart attacks,
-
UNDERSTANDING THE NEW VALUE PROPOSITION FOR THE NHS
Developing a Costed Integrated Patient Scenario, such as this for chronic kidney disease, can be a powerful way of evaluating the different components in a patient’s care, and showing, in ... reinvigorate the disease-specific service improvement
-
Cardiovascular disease: The scale of the challenge
a factor, and where are the opportunities for the system to collectively do better to prevent disease, disability, and death? ... Thousands of cases of stroke, diabetes, heart failure and kidney disease could and should be prevented every year yet
-
Moving Away from Hospital-Centered Care: Barriers & Opportunities
David Barthel, CEO of Health Logic Interactive Inc., discusses their lab-on-chip, point-of-care platform technology for CKD. He also explores the issues with the hospital-centered model of care, shares his tips for new biotech startups and leaders,
-
#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
However, once these trials are divided up into specific diseases the underrepresentation becomes clearer, especially in the fields of cardiovascular diseases, hepatitis, HIV, chronic kidney disease and digestive diseases.
More from PMHub
Approximately 1 fully matching, plus 9 partially matching documents found.
Subscribe to our email news alerts
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Sanofi's frexalimab shows promise in relapsing forms of MS
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Amgen reports positive results for Otezla in psoriatic arthritis
- Supply chain challenges in 2023
- Whitepaper: Closing the gap with compelling healthcare communications
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
No results were found
PMHub
Say Communications
We focus on what matters most…. Driven by insight, expertise and fresh thinking, our award-winning communications programmes are designed to...
Latest intelligence
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
